Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2014

View Archived Issues

Takeda Pharmaceuticals charts milestones of second quarter of fiscal 2014

Daiichi Sankyo presents highlights of second quarter of fiscal 2014

Fujifilm to invest in PET radiopharmaceuticals

Xoma opens enrollment in phase III study of gevokizumab for pyoderma gangrenosum

AstraZeneca and Pharmacyclics collaborate on combination trials of ibrutinib in oncology

Cabozantinib extends progression-free survival in phase II trial in NSCLC

Astellas and Proteostasis Therapeutics form collaboration targeting the unfolded protein response

LEO Pharma licenses Japan Tobacco's JTE-052 for dermatology applications

Research uncovers novel gene mutations underlying familial hypertrophic cardiomyopathy

BioLineRx reports final results of phase I/II study for BL-7010

Alion and Medical Prognosis Institute to identify response biomarkers for ion channel inhibitor

Novel cystine derivatives inhibit stone formation in vivo

Aegerion Pharmaceuticals to acquire Myalept from AstraZeneca

New pan-RAF inhibitors effective in melanomas resistant to BRAF or BRAF/MEK inhibitors

Effectiveness of a bumped kinase inhibitor against toxoplasmosis

Novel ACC2 inhibitors disclosed by Boehringer Ingelheim

Incyte divulges novel FGFR-1, -2 and -3 inhibitors

Sage Therapeutics synthesizes novel GABA(A) receptor modulators

Astellas Pharma discloses new D1 receptor PAMs

Actelion researchers present novel antibacterial compounds

Investigators at CSIR report new anticancer rohitukine analogues

Beloranib as promising treatment of obesity and food-related behavior in Prader-Willi Syndrome

Spark Therapeutics' SPK-RPE65 receives FDA breakthrough therapy designation

Gilead files NDA for elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for HIV

FDA advisory committee recommends approval of Triferic

FDA issues complete response letter to AEterna Zentaris for Macrilen NDA

F-star spins off assets into F-star Beta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...